We develop a proprietary, stand-alone platform that delivers lab-grade accuracy with rapid and simple testing. Leveraging precise pathogen identification and point mutation detection, our technology provides the clarity and confidence needed for timely, effective treatment decisions.
Head of biology
Clinical dev. assistant.
R&D scientist
Yoni Nethanyahu St., 6, Or Yehuda
Co-founder, CEO
Dr. Roy Rabinowitz is the co-founder and CEO of Kanso Diagnostics. He holds a Ph.D. in molecular biology from Tel Aviv University, where he investigated the specificity and safety of the CRISPR gene-editing system. He authored six peer-reviewed papers and filed six patents. His research was recognized with number of awards and scholarships, including the prestigious Dan David Prize scholarship and TEVA’s BioInnovation Forum.
Co-founder, CTO
Omer Stoller is the co-founder and CTO of Kanso Diagnostics. He holds a B.Sc. in Mechanical Engineering and an MBA, both from the Technion – Israel Institute of Technology. Omer brings extensive expertise in developing advanced mechanical systems, backed by his experience leading multidisciplinary projects in the R&D division of one of Israel’s top defence companies. He has been instrumental in leading complex opto-mechanical projects from initial concept to fully functional prototypes.
CMO
Yoav Golan MD MS FIDSA is an Infectious diseases physician at Tufts Medical Center in Boston, MA. He graduated from the Hebrew University, Hadassah School of Medicine in Jerusalem, Israel and is trained in clinical research, epidemiology, and statistics. Over the past 15 years, Dr. Golan has been involved in patient care, clinical research, and the development of novel anti-infectives and management paradigms. His research is focusing on patient risk stratification and its relation to the effectiveness of novel interventions, with emphasis on severe life-threatening infections and infections caused by antibiotic-resistant bacteria. Dr Golan is the director of the Tufts Clinical and Translational Research Center (CTRC). In addition, he serves as the medical director of the Delhaize America Immunization program and has served as Chief Medical Officer for Appili Therapeutics, leading the clinical development of an anti-COVID small molecule. Dr. Golan has served as a PI in multiple clinical trials and published numerous articles including in the New England Journal of Medicine, JAMA, Annals of Internal Medicine, Lancet Infectious Diseases and Clinical Infectious Diseases.
CSO
Dr. Shakked Halperin is a serial entrepreneur, inventor, and bioengineer. He holds a Master’s from the University of Cambridge, sponsored by the Bill and Melinda Gates Foundation, and a PhD from UC Berkeley, sponsored by the US National Science Foundation. Dr. Halperin served as the founder and CEO of Rewrite Therapeutics and Replace Therapeutics, which used his inventions of CRISPR-guided DNA polymerases and CRISPR-guided DNA ligases to develop precision genome editing medicines. Since leading both companies to successful acquisitions, Dr. Halperin now focuses on supporting other genomic biotechnology startups as an angel investor, advisor, board member, and executive.
